OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort
Michael B. VanElzakker, Emma M. Tillman, Lael M. Yonker, et al.
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 6, pp. 603-609
Open Access | Times Cited: 24
Michael B. VanElzakker, Emma M. Tillman, Lael M. Yonker, et al.
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 6, pp. 603-609
Open Access | Times Cited: 24
Showing 24 citing articles:
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 6
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 6
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
Isabelle Sermet‐Gaudelus, Sihem Benaboud, S. Bui, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 117-120
Closed Access | Times Cited: 4
Isabelle Sermet‐Gaudelus, Sihem Benaboud, S. Bui, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 117-120
Closed Access | Times Cited: 4
Mental disorders in patients with cystic fibrosis
A. Klimenko, A Aleksandrova
The Clinician (2025) Vol. 18, Iss. 4, pp. 12-19
Open Access
A. Klimenko, A Aleksandrova
The Clinician (2025) Vol. 18, Iss. 4, pp. 12-19
Open Access
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real‐World Evidence From an Italian Single‐Center Study
Nicola Perrotta, Luigi Angelo Fiorito, G Casini, et al.
Pharmacology Research & Perspectives (2025) Vol. 13, Iss. 2
Open Access
Nicola Perrotta, Luigi Angelo Fiorito, G Casini, et al.
Pharmacology Research & Perspectives (2025) Vol. 13, Iss. 2
Open Access
Recent developments in cystic fibrosis drug discovery: where are we today?
Miquéias Lopes‐Pacheco, Amanda Winters, JaNise J. Jackson, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Miquéias Lopes‐Pacheco, Amanda Winters, JaNise J. Jackson, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)
Dinu Zinovie Ciobanu, Nara Liessi, Valeria Tomati, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 6, pp. 1167-1172
Open Access | Times Cited: 4
Dinu Zinovie Ciobanu, Nara Liessi, Valeria Tomati, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 6, pp. 1167-1172
Open Access | Times Cited: 4
Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve
Maggie Harrigan, Anna M. Georgiopoulos, Alexandra L. Quittner, et al.
BMJ Open Respiratory Research (2025) Vol. 12, Iss. 1, pp. e002606-e002606
Open Access
Maggie Harrigan, Anna M. Georgiopoulos, Alexandra L. Quittner, et al.
BMJ Open Respiratory Research (2025) Vol. 12, Iss. 1, pp. e002606-e002606
Open Access
Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121
Aaron Kolski‐Andreaco, Stefanie Taiclet, Michael M. Myerburg, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 16
Open Access | Times Cited: 2
Aaron Kolski‐Andreaco, Stefanie Taiclet, Michael M. Myerburg, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 16
Open Access | Times Cited: 2
Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
Cameron J. McKinzie, Stephanie Duehlmeyer, Charissa W. Kam, et al.
Pediatric Pulmonology (2024)
Closed Access | Times Cited: 2
Cameron J. McKinzie, Stephanie Duehlmeyer, Charissa W. Kam, et al.
Pediatric Pulmonology (2024)
Closed Access | Times Cited: 2
Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
Harish Pudukodu, Margret Z. Powell, Agathe Ceppe, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 9
Open Access | Times Cited: 1
Harish Pudukodu, Margret Z. Powell, Agathe Ceppe, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 9
Open Access | Times Cited: 1
Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases
Minsoo Kim, Lars Plate
Israel Journal of Chemistry (2024) Vol. 64, Iss. 12
Closed Access | Times Cited: 1
Minsoo Kim, Lars Plate
Israel Journal of Chemistry (2024) Vol. 64, Iss. 12
Closed Access | Times Cited: 1
Prevalence of cannabidiol use in persons with cystic fibrosis
Emma M. Tillman, Katherine A. Gallaway, Abi Colwell, et al.
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3790-3792
Open Access | Times Cited: 1
Emma M. Tillman, Katherine A. Gallaway, Abi Colwell, et al.
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3790-3792
Open Access | Times Cited: 1
Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies
Jacob O'Connor, D. Nazareth, Dennis Wat, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 1
Jacob O'Connor, D. Nazareth, Dennis Wat, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 1
New drugs, new challenges in cystic fibrosis care
Isabelle Fajac, Pierre–Régis Burgel, C. Martín
European Respiratory Review (2024) Vol. 33, Iss. 173, pp. 240045-240045
Open Access | Times Cited: 1
Isabelle Fajac, Pierre–Régis Burgel, C. Martín
European Respiratory Review (2024) Vol. 33, Iss. 173, pp. 240045-240045
Open Access | Times Cited: 1
Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group
Christina J. Bathgate, David A. Fedele, Emma M. Tillman, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 1
Christina J. Bathgate, David A. Fedele, Emma M. Tillman, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 1
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
Zhongyu Liu, Justin D. Anderson, Natalie R. Rose, et al.
Pulmonary Pharmacology & Therapeutics (2024) Vol. 86, pp. 102314-102314
Closed Access
Zhongyu Liu, Justin D. Anderson, Natalie R. Rose, et al.
Pulmonary Pharmacology & Therapeutics (2024) Vol. 86, pp. 102314-102314
Closed Access
Prevalence of psychotropic medication dispensing to people living with cystic fibrosis in Australia: 2013–2022
Louise Lord, Peter Wark, Mark Hew, et al.
Journal of Psychosomatic Research (2024) Vol. 186, pp. 111877-111877
Open Access
Louise Lord, Peter Wark, Mark Hew, et al.
Journal of Psychosomatic Research (2024) Vol. 186, pp. 111877-111877
Open Access
Mood Swings and Irritability in a Patient With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy
Yu-Tung Lan, Yu-Ting Wung
Journal of Clinical Psychopharmacology (2024) Vol. 44, Iss. 5, pp. 528-530
Closed Access
Yu-Tung Lan, Yu-Ting Wung
Journal of Clinical Psychopharmacology (2024) Vol. 44, Iss. 5, pp. 528-530
Closed Access
Diagnosis and treatment of ADHD in pediatric patients during the first year of elexacaftor/tezacaftor/ivacaftor
Kimberly Pasley, Mary Lynn Dell, Anne M. May
Pediatric Pulmonology (2024)
Closed Access
Kimberly Pasley, Mary Lynn Dell, Anne M. May
Pediatric Pulmonology (2024)
Closed Access
Elexacaftor/Tezacaftor/Ivacaftor, a game-changer in Cystic Fibrosis: The Portuguese experience.
Elsa Fragoso, Rita Boaventura, Luís Almeida, et al.
Pulmonary Pharmacology & Therapeutics (2024), pp. 102328-102328
Closed Access
Elsa Fragoso, Rita Boaventura, Luís Almeida, et al.
Pulmonary Pharmacology & Therapeutics (2024), pp. 102328-102328
Closed Access
Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center
Lena Papadakis, Tayler Stander, Jacqueline Mombourquette, et al.
Pediatric Pulmonology (2024)
Open Access
Lena Papadakis, Tayler Stander, Jacqueline Mombourquette, et al.
Pediatric Pulmonology (2024)
Open Access
Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis
Rebecca S. Pettit, Colleen Sakon, Kerry A. Kinney, et al.
Pediatric Pulmonology (2024)
Open Access
Rebecca S. Pettit, Colleen Sakon, Kerry A. Kinney, et al.
Pediatric Pulmonology (2024)
Open Access
Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy
Jennifer L. Goralski, Asha N. Talati, Emily E. Hardisty, et al.
Obstetrics and Gynecology (2024) Vol. 145, Iss. 1, pp. 47-54
Open Access
Jennifer L. Goralski, Asha N. Talati, Emily E. Hardisty, et al.
Obstetrics and Gynecology (2024) Vol. 145, Iss. 1, pp. 47-54
Open Access
The impact of CFTR modulators on mental health: Moving the field forward
Anna M. Georgiopoulos, Emma M. Tillman
Journal of Cystic Fibrosis (2024)
Closed Access
Anna M. Georgiopoulos, Emma M. Tillman
Journal of Cystic Fibrosis (2024)
Closed Access
